Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group

Please use this identifier to cite or link to this item: https://doi.org/10.1038/bmt.2014.65

Title:	Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group
Authors:	Tse, E. Chan, T.S.Y. Koh, L.-P. Chng, W.-J. Kim, W.-S. Tang, T. Lim, S.-T. Lie, A.K.W. Kwong, Y.-L.
Issue Date:	28-Apr-2014
Citation:	Tse, E., Chan, T.S.Y., Koh, L.-P., Chng, W.-J., Kim, W.-S., Tang, T., Lim, S.-T., Lie, A.K.W., Kwong, Y.-L. (2014-04-28). Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplantation 49 (7) : 902-906. ScholarBank@NUS Repository. https://doi.org/10.1038/bmt.2014.65
Abstract:	Eighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced intensity, N=4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P
Source Title:	Bone Marrow Transplantation
URI:	http://scholarbank.nus.edu.sg/handle/10635/126877
ISSN:	02683369
DOI:	10.1038/bmt.2014.65
Appears in Collections:	Staff Publications

There are no files associated with this item.

Check